New EU Filings
Executive Summary
Ryzneuta, Evive Biotech’s treatment for chemotherapy-induced neutropenia in cancer patients, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
You may also be interested in...
Nine Major Approval Decisions To Watch In Early 2022
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
Rare EU Fast-Track Nod For Sanofi Genzyme's Olipudase Alfa
Only three planned marketing authorization applications are known to have been granted accelerated assessment status by the European Medicines Agency between July and October this year.
First-Of Kind BMS Drugs Among Myriad New Filings In EU
Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.